24 episodios
EconRx Aaron Young
-
- Salud y forma física
In this show we dive into the business of the US healthcare system. Why are some of my medications covered by insurance but not others? What does it mean for a provider to be "in-network?" Above all, WHERE DO OUR HEALTHCARE DOLLARS GO??! We want to understand and answer these questions, and we want you to come with us on this journey.
-
Alzheimer's Boom or Bust
Aducanumab (brand name Aduhelm) drew headlines when it was approved by the FDA in 2021 against the recommendations of the FDA advisory committee. Today it's almost commercially dead. On this episode are joined by P4 student Ise Brockmann to dive into aducanumab's story.
email: econrxpodcast@gmail.com
Twitter/Instagram: @EconRx
LinkedIn: www.linkedin.com/company/econrx
Website: https://econrx.libsyn.com/ -
$35 Insulin Cap
Capping patient out-of-pocket costs for insulin has been a popular move for legislators, most recently by the US House. On this episode we weigh the Pros, Cons, and viral reactions to this move including lowering vs. shifting costs, ADA guidelines, and political theater.
email: econrxpodcast@gmail.com
Twitter/Instagram: @EconRx
LinkedIn: www.linkedin.com/company/econrx
Website: https://econrx.libsyn.com/ -
Testing Woes & Ivermectin
After explaining a HORRENDOUS mistake made recently by the NABP and the oversight of NAPLEX testing that affected one of our own, we decided it's high time we dove into the controversy around the use of ivermectin against COVID-19. Social media and mainstream news can be confusing, so we tried to summarize while sticking to what is known. If we missed something, please let us know!
email: econrxpodcast@gmail.com
Twitter/Instagram: @EconRx
LinkedIn: www.linkedin.com/company/econrx
Website: https://econrx.libsyn.com/ -
Blueberry Pharmacy
On this episode we were blessed to have on Kyle McCormick, owner/operator of Blueberry Pharmacy, to explain his unique (but traditionally familiar) business model. Blueberry operates on a cost-plus model and DOES NOT ACCEPT INSURANCE. Crazy? Maybe not. Kyle explains why he thinks we need different payment systems for cheap generics than expensive brand names, circumventing PBMs when they aren't necessary.
https://blueberrypharmacy.com/
email: econrxpodcast@gmail.com
Twitter/Instagram: @EconRx
LinkedIn: www.linkedin.com/company/econrx
Website: https://econrx.libsyn.com/ -
[NEWSFLASH] Amazon: Usual & Customary
The Twittersphere recently noticed that quoted savings on Amazon Pharmacy are a little bit unrealistic. On this episode we break down how a pharmacy's "Usual & Customary" price SHOULD be calculated, what it is used for, and what Amazon's crazy numbers say about their pharmacy business model.
email: econrxpodcast@gmail.com
Twitter/Instagram: @EconRx
LinkedIn: www.linkedin.com/company/econrx
Website: https://econrx.libsyn.com/ -
US Drug Supply Chain
The COVID-19 pandemic highlighted many weaknesses in the US Drug Supply Chain's dependence on foreign production (similar to toilet paper, masks, etc.). The Biden White House recently announced plans to address supply chain weaknesses to prevent future shortages due to overseas dependence.
email: econrxpodcast@gmail.com
Twitter/Instagram: @EconRx
LinkedIn: www.linkedin.com/company/econrx
Website: https://econrx.libsyn.com/